Clinical Trial Update: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation [Phase 2]

View source ↗

Summary

A Phase 2 study of PRT3789 in combination with pembrolizumab for SMARCA4-mutant advanced or metastatic solid tumors was terminated. The study included esophagea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• PRT3789
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Prelude Therapeutics | Conditions: Advanced Solid Tumor, Esophageal Cancer | Phase 2 | Status: TERMINATED